PubMed Health⌕ Search

Biomedical subjects

T Laperche

Publications and source records attributed to T Laperche.

40 records · Page 3Linked to original sources
PubMed1990

[Converting enzyme inhibitors and cardiac insufficiency: current findings and perspectives].

Angiotensin-converting enzyme inhibitors are mixed vasodilators with a prolonged sustained effect in chronic heart failure. They also act on the reactivity of peripheral circulation, on ventricular remodelling after myocardial infarction, on myocardial hypertrophy in arterial hypertension and on ventricular hyperexcitability. They alleviate the symptoms of symptomatic heart failure, and they constitute the only treatment that has been able to improve the survival of patients with the most severe heart failure. Several studies are in progress to determine whether these drugs should be used as first-line therapy.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1990

[Influence of medical treatments on the functional status in patients with chronic cardiac insufficiency].

The discordance frequently observed between the hemodynamic effects of treatment and change in functional status may be explained by the fact that symptoms are related more to the circulatory changes caused by the heart failure than the heart failure itself. This is why angiotensin converting enzyme inhibitors and controlled exercise training improve exercise capacity of patients with chronic cardiac failure more than inotropic agents and direct vasodilator therapy, partly because of their marked beneficial effect on regional blood flow.

Cardiovascular Agents↗
PubMedDate not supplied

[Prescription, assay and interpretation of cardiac troponins tests: guidelines from SFBC-CNBC troponin working group].

Troponin (I or T) has become the gold-standard marker in acute coronary syndromes during the last few years, as confirmed by a national survey realized within french clinical chemists, cardiologists and emergency practitioners. The importance of this marker and the heterogeneousness of circulating forms of troponin after myocardial necrosis fully justify international studies about standardization of this assay, which is a central bulk to reach a global market coherence. Checking analytical problems, although necessary, must be absolutely associated with an informed clinical interpretation. The knowledge of the crucial thresholds of each assay, the kinetic curves and the specificity limits of troponin assays allow the best use of their potential in diagnosis and prognosis together with an optimal patient care in very different clinical settings, in addition to others clinical and technical arguments. The quality improvement through successive generations of assay kits must nowadays persuade the physicians never to ignore a significant and valid troponin increase, which mainly reveals a cardiac injury, whatever its origin.

Acute Disease↗